Paul Frankel
- Oncology top 1%
- Cancer Treatment and Pharmacology 45
- Cancer Immunotherapy and Biomarkers 24
- HER2/EGFR in Cancer Research 19
- Colorectal Cancer Treatments and Studies 17
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 18
- Breast Cancer Treatment Studies 16
-
- Advanced Breast Cancer Therapies 23
- Hematology top 5%
- Molecular Biology top 5%
- Histone Deacetylase Inhibitors Research 19
- Co-authors
- David R. GandaraGeorge SomloChristopher RuelTimothy W. SynoldJames H. DoroshowIgor Espinoza‐DelgadoJoanne MortimerRobert J. Morgan
- Journals
- Journal of Clinical Oncology (58 papers)SHILAP Revista de lepidopterología (1 paper)Blood (14 papers)
- Partner nations
- United StatesGermanyTaiwan
In The Last Decade
Paul Frankel
206 papers receiving 4.1k citations
Peers
Comparison fields: 5 of 116
- Oncology 1.9k
- Cancer Research 658
- Pulmonary and Respiratory Medicine 967
- Hematology 321
- Molecular Biology 1.8k
Countries citing papers authored by Paul Frankel
This map shows the geographic impact of Paul Frankel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Frankel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Frankel more than expected).
Fields of papers citing papers by Paul Frankel
This network shows the impact of papers produced by Paul Frankel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Frankel. The network helps show where Paul Frankel may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Paul Frankel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 13 | |
| 4 | 2023 | 3 | |
| 5 | 2023 | 14 | |
| 6 | 2022 | 9 | |
| 7 | 2022 | 6 | |
| 8 | 2021 | 2 | |
| 9 | 2021 | 7 | |
| 10 | 2021 | 8 | |
| 11 | 2020 | 1 | |
| 12 | 2019 | 25 | |
| 13 | 2019 | 25 | |
| 14 | 2018 | 54 | |
| 15 | 2017 | 11 | |
| 16 | 2016 | 127 | |
| 17 | 2011 | 62 | |
| 18 | 2008 | 23 | |
| 19 | A randomized phase II neoadjuvant trial in patients with stages II-III and inflammatory breast cancer. | 2007 | 2 |
| 20 | SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. | 2003 | 51 |
About Paul Frankel
Paul Frankel is a scholar working on Oncology, Cancer Research and Hematology, having authored 214 papers that have together received 4.1k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (45 papers), Cancer Immunotherapy and Biomarkers (24 papers), Advanced Breast Cancer Therapies (23 papers), Histone Deacetylase Inhibitors Research (19 papers), HER2/EGFR in Cancer Research (19 papers), Cancer Genomics and Diagnostics (18 papers), Colorectal Cancer Treatments and Studies (17 papers) and Breast Cancer Treatment Studies (16 papers). The work is most often cited by research in Oncology (1.9k citations), Cancer Research (658 citations) and Pulmonary and Respiratory Medicine (967 citations). Paul Frankel has collaborated with scholars based in United States, Germany and Taiwan. Frequent co-authors include David R. Gandara, George Somlo, Christopher Ruel, Timothy W. Synold, James H. Doroshow, Igor Espinoza‐Delgado, Joanne Mortimer, Robert J. Morgan, Marianna Koczywas and Edward M. Newman. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.